tbuckley/cabot-search huggingface dataset:
Abstract 334: Acute Effects of Nonexcitatory Electrical Stimulation During Systole in Human-induced Pluripotent Stem Cell Derived Cardiomyocytes
Authors: TK Feaster, Maura Casciola, Trent Robertson, Suran Galappaththige, Richard A Gray, Ksenia Blinova
Journal: Circulation Research (2020)

Cardiac contractility modulation (CCM) is a cardiac therapy whereby non-excitatory electrical simulations are delivered during the absolute refractory period of the cardiac cycle. CCM is indicated for patients with heart failure (Class III/IV) and reduced ejection fraction. We previously evaluated the effects of CCM and found isolated adult rabbit cardiomyocytes (rabbit-CMs) display a transient increase in calcium and contractility. In the present study, we sought to extend these results to human cardiomyocytes using human stem-cell cardiomyocytes (hiPSC-CMs). hiPSC-CMs were studied in both monolayer and isolated cells and results compared to that of rabbit-CMs. Contractility, calcium handling and electrophysiology was evaluated by image and fluorescence analysis. CCM was applied with a custom device covering a range of pulse parameters including standard clinical parameters (Figure 1). Pacing threshold was determined and stimulation performed at twice the diastolic capture threshold. Robust contractile response was observed at 16 V/cm, 70 mA for pacing and 28 V/cm, 120 mA for CCM. Under these conditions hiPSC-CMs and rabbit-CMs displayed increased contraction amplitude of 30 % (1.79 a.u., CCM vs 1.38 a.u., Control) and 22 % (3.67 a.u., CCM vs 3.00 a.u., Control) respectively and faster kinetics that subsided when the CCM signal was eliminated. This study provides a comprehensive characterization of the effects of CCM on hiPSC-CMs and rabbit-CMs in parallel under identical experimental conditions. These data provide the first study of CCM in hiPSC-CMs and demonstrates the potential utility of hiPSC-CMs to evaluate safety and effectiveness of cardiac medical devices.
Generalized Pruriginous Eruption on a Patient With Leukemia
Authors: Lucía Núñez-Hipólito, Cristina Moya-Martínez, Luis Requena
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Deep-Learning Resources for Studying Glycan-Mediated Host-Microbe Interactions
Authors: Daniel Bojar, Rani K. Powers, Diogo M. Camacho, James J. Collins
Journal: Cell Host & Microbe (2020)

Glycans, the most diverse biopolymer, are shaped by evolutionary pressures stemming from host-microbe interactions. Here, we present machine learning and bioinformatics methods to leverage the evolutionary information present in glycans to gain insights into how pathogens and commensals interact with hosts. By using techniques from natural language processing, we develop deep-learning models for glycans that are trained on a curated dataset of 19,299 unique glycans and can be used to study and predict glycan functions. We show that these models can be utilized to predict glycan immunogenicity and the pathogenicity of bacterial strains, as well as investigate glycan-mediated immune evasion via molecular mimicry. We also develop glycan-alignment methods and use these to analyze virulence-determining glycan motifs in the capsular polysaccharides of bacterial pathogens. These resources enable one to identify and study glycan motifs involved in immunogenicity, pathogenicity, molecular mimicry, and immune evasion, expanding our understanding of host-microbe interactions.
AB0908 ASSESSMENT OF THE IMPACT OF THE LEAN MASS WITH BODY COMPOSITION BY DUAL-ENERGY X-RAY ABSORPTIOMETRY ON THE BONE MINERAL DENSITY
Authors: M. Nikolov, N. Nikolov
Journal: Annals of the Rheumatic Diseases (2020)

Background: Lean mass, mainly composed of muscle, has been correlated to bone mineral density (BMD) [4]. Studies reported that lean mass has an important impact on BMD not only in young women but also in postmenopausal women [1]. High lean mass is more favorable for the BMD than low lean mass. Some studies suggested that genetic factors responsible for both lean mass and BMD are shared [3]. Low muscle mass and low BMD could impair the quality of the patient’s life [2, 5]. Objectives: The aim of this study is to assess the impact of the lean mass with body composition by dual-energy X-ray absorptiometry on the bone mineral density. Methods: 107 women underwent body composition analysis by dual-energy X-ray absorptiometry (DXA). Lean mass in kg and BMD in kg/cm2 were analyzed. Normal BMD was defined as T-score &gt; -1.0 standard deviation (SD). Osteopenia was defined as T-score between -1.0 SDs and -2.5 SDs and osteoporosis was defined as T-score ≤ - 2.5 SDs. Results: The mean age of the women was 57 years (yrs.) ± 11 yrs. (range 41 yrs. – 80 yrs.). Subjects had mean weight of 75 kg ± 12 kg (range 50 kg – 110 kg) and mean height of 156 cm ± 9 cm (range 151 cm – 172 cm). 73/107 women (68.2%) were with normal BMD, 24/107 women (22.4%) were with osteopenia and 10/107 women (9.4%) were with osteoporosis. Lean mass differed significantly between the groups (p = 0.000). Women with normal BMD had the highest mean lean mass (58.47 kg) and the mean lean mass of the women with osteopenia and osteoporosis decreased as follow: 47.56 kg for women with osteopenia and 36.22 kg for women with osteoporosis. Conclusion: Women with osteoporosis have the lowest lean mass compared to the women with osteopenia and osteoporosis. References: [1]Ilesanmi-Oyelere BL, Coad J, Roy N, Kruger MC. Lean Body Mass in the Prediction of Bone Mineral Density in Postmenopausal Women. Biores Open Access. 2018;7(1):150–158. Published 2018 Oct 10. doi:10.1089/biores.2018.0025. [2]Kirilov N., Vladeva SG, Kirilova E. Assessment on the Improvement of the Quality of Life after One Year of Regular Physical Activity and Treatment in Patients with Postmenopausal OsteoporosisCOR 2017: 19th International Conference on Orthopedics and Rheumatology Miami, USA March 9 - 10, 2017, WASET, Paper Code 17US030051. [3]Nguyen TV, Howard GM, Kelly PJ, Eisman JA. Bone mass, lean mass, and fat mass: same genes or same environments? Am J Epidemiol. 1998 Jan 1;147(1):3-16. [4]Patel HP, Dawson A, Westbury LD, et al. Muscle Mass, Muscle Morphology and Bone Health Among Community-Dwelling Older Men: Findings from the Hertfordshire Sarcopenia Study (HSS). Calcif Tissue Int. 2018;103(1):35–43. doi:10.1007/s00223-018-0388-2. [5]Kirilova E, Kirilov N, Vladeva S. A study on the physical activity in women with decreased bone mineral density. Abstract book 13 th science conference MC, Pleven Disclosure of Interests: None declared
Rapid Engraftment, Immune Recovery, and Resolution of Transfusion Dependence in Treatment-Refractory Severe Aplastic Anemia Following Transplantation with Ex Vivo Expanded Umbilical Cord Blood (Omidubicel)
Authors: Mohamed Samour, Georg Aue, Joseph Clara, Jennifer Wilder, Robert Reger, Rosa Nadal Rios, Kate Stringaris, Brian Wells, Lisa Cook, Kristen Gunn, Reem A Shalabi, Josef Rivero, Patricia Prince, David F. Stroncek, Willy A. Flegel, Xin Tian, Richard W. Childs
Journal: Blood (2020)
MICRORNA 99B AND LET7A AS DIAGNOSTIC PARAMETERS IN MYELODYSPLASTIC SYNDROME
Authors: Inga Mandac Rogulj, Mirjana Mariana Kardum Paro, Vibor Milunovic, Karla Mišura Jakobac, Viktor Zatezalo, Bojana Acamovic Stipinovic, Martina Bogeljic Patekar, Marin Kursar, Marko Martinovic, Goran Rincic, Delfa Radic Kristo, Slobodanka Ostojic Kolonic
Journal: HemaSphere (2020)
High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics
Authors: Jordan Gauthier, Cassie Chou, Alexandre V. Hirayama, Salvatore Fiorenza, Alyssa Sheih, Barbara S. Pender, Tinh-Doan Phi, Rachel Steinmetz, Abby Jamieson, Delaney R Kirchmeier, Henna N Di, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle
Journal: Blood (2020)
Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase α
Authors: Panagiotis Efentakis, Sofia Lamprou, Polyzois Dimas, Constantinos Dimitriou, Manousos Makridakis, Maria Tsoumani, Asimina Papanikolaou, Efstathios Kastritis, Antonia Vlachou, Meletios A Dimopoulos, Ioanna Andreadou, Evangelos Terpos
Journal: Blood (2020)
Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis
Authors: Carlton D. Dampier, Marilyn J. Telen, Ted Wun, Wally R Smith, R. Clark Brown, Payal Desai, Fuad A El Rassi, Julie Kanter, Beng R. Fuh, Yves D. Pastore, Jennifer A. Rothman, James G. Taylor, David Readett, Jay N Lozier, John L. Magnani, Helen M Thackray, Kathryn L. Hassell
Journal: Blood (2020)
Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor
Authors: Natalia Baran, Alessia Lodi, Yogesh Dhungana, Shannon RENEE Sweeney, Pandey Renu, Shelley Herbrich, Fieke W Hoff, Anna Skwarska, Mecit Kaplan, Vinitha Mary Kuruvilla, Antonio Cavazos, Marc Warmoes, Shanti Rojas-Sutterlin, Andre Haman, Diogo Troggian Veiga, Ken Furudate, Helen Ma, Karine Harutyunyan, Wentao Yang, Mihai Gagea, Di Du, May Daher, Luciana Melo Garcia, Sujan Piya, Vivian Ruvolo, Sriram Shanmugavelandy, Ningping Feng, Jason P Gay, Ondrej Havranek, Jared Henderson, Katarzyna Tomczak, Marcin Kaminski, Daniel Herranz, Adolfo Ferrando, Elias Jabbour, Maria E Di Francesco, David T. Teachey, Terzah M. Horton, Katayoun Rezvani, Jun J. Yang, Steven M. Kornblau, Eric Davis, Koichi Takahashi, Michael Andreeff, Joseph R Marszalek, Philip Lorenzi, Jiyang Yu, Stefano Tiziani, Trang Hoang, Marina Konopleva
Journal: Blood (2020)
Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant
Authors: Prioty Islam, Haesu Jin, Felicia Cao, Lauren M. Bohannon, Yi Ren, Nelson J. Chao, Taewoong Choi, Cristina Gasparetto, Mitchell E. Horwitz, Gwynn D. Long, Richard D. Lopez, David A Rizzieri, Stefanie Sarantopoulos, Anthony D. Sung
Journal: Blood (2020)
Studying Immunophenotypic Modulation at Different Time Points of Chemotherapy : A Walk through the Disease Course in 121 Pediatric B Lymphoblastic Leukemia Cases; Providing Implications for MRD Detection
Authors: Omer Javed, Neelum Mansoor, Hamza Khan, Naeem Jabbar, Talha Israr, Saba Jamal, Fatima Meraj
Journal: Blood (2020)
Geographic Disparities of Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients in Virginia
Authors: Joseph Mock, Cecilia Nguyen, Puja C. Arora, Courtney Heron, Karen K. Ballen, Lih-Wen Mau, Christa Lea Meyer, Rajesh Balkrishnan, Steven M Devine
Journal: Blood (2020)
Molecular Subtypes with Distinct Clinical Phenotypes and Actionable Targets in Adult B Cell Precursor ALL Treatment According to GMALL Protocols
Authors: Lorenz Bastian, Sonja Hänzelmann, Martin Neumann, Alina Hartmann, Thomas Burmeister, Stefan Schwartz, Walter Fiedler, Mustafa Kondakci, Andreas Viardot, Folker Schneller, Christoph Faul, Max S. Topp, Sören Franzenburg, Andre Franke, Heiko Trautmann, Nicola Goekbuget, Monika Brüggemann, Claudia D Baldus
Journal: Blood (2020)
Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry
Authors: Pilar Martínez, Tomás Palanques Pastor, Jose Luiz Lopez Lorenzo, Javier Cornago Navascués, Gabriela Rodriguez-Macías, Isabel Cano, Montserrat Arnan Sangerman, María-Belén Vidriales, Jesús Lorenzo Algarra, Maria Angeles Foncillas, Pilar Herrera Puente, Carmen Botella, Susana Vives, Angela Figuera Alvarez, Laida Cuevas Palomares, Marta Sobas, Alejandro Contento-Gonzalo, Rebeca Cuello, María Elena Amutio Diez, Maria Dunia De Miguel, Begoña Navas, Juan Miguel Bergua Burgues, Teresa Bernal del Castillo, María Carmen Mateos Rodríguez, Erik de Cabo López, Ana Carolina Franco Villegas, Raimundo García-Boyero, Cristian Escolano Escobar, Cristina Seri, Carlos Cervero, Alicia Roldán Pérez, Maria Lourdes Hermosin, Marta Cervera, María Teresa Olave, Paola Sandra Villafuerte Gutierrez, Almudena De Laiglesia, Josefina Serrano, María Josefa Najera Irazu, Jose Luis Piñana Sanchez, Miguel Ángel Sanz, Joaquin Martinez-Lopez, Pau Montesinos
Journal: Blood (2020)
Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease
Authors: Sarju Ganatra, Sourbha S. Dani, Robert Redd, Kimberly Rieger-Christ, Rushin Patel, Rohan Parikh, Aarti Asnani, Vigyan Bang, Katherine Shreyder, Simarjeet S. Brar, Amitoj Singh, Dhruv S. Kazi, Avirup Guha, Salim S. Hayek, Ana Barac, Krishna S. Gunturu, Corrine Zarwan, Anne C. Mosenthal, Shakeeb A. Yunus, Amudha Kumar, Jaymin M. Patel, Richard D. Patten, David M. Venesy, Sachin P. Shah, Frederic S. Resnic, Anju Nohria, Suzanne J. Baron
Journal: Journal of the National Comprehensive Cancer Network (2021)

Background: Cancer and cardiovascular disease (CVD) are independently associated with adverse outcomes in patients with COVID-19. However, outcomes in patients with COVID-19 with both cancer and comorbid CVD are unknown. Methods: This retrospective study included 2,476 patients who tested positive for SARS-CoV-2 at 4 Massachusetts hospitals between March 11 and May 21, 2020. Patients were stratified by a history of either cancer (n=195) or CVD (n=414) and subsequently by the presence of both cancer and CVD (n=82). We compared outcomes between patients with and without cancer and patients with both cancer and CVD compared with patients with either condition alone. The primary endpoint was COVID-19–associated severe disease, defined as a composite of the need for mechanical ventilation, shock, or death. Secondary endpoints included death, shock, need for mechanical ventilation, need for supplemental oxygen, arrhythmia, venous thromboembolism, encephalopathy, abnormal troponin level, and length of stay. Results: Multivariable analysis identified cancer as an independent predictor of COVID-19–associated severe disease among all infected patients. Patients with cancer were more likely to develop COVID-19–associated severe disease than were those without cancer (hazard ratio [HR], 2.02; 95% CI, 1.53–2.68; P &lt;.001). Furthermore, patients with both cancer and CVD had a higher likelihood of COVID-19–associated severe disease compared with those with either cancer (HR, 1.86; 95% CI, 1.11–3.10; P =.02) or CVD (HR, 1.79; 95% CI, 1.21–2.66; P =.004) alone. Patients died more frequently if they had both cancer and CVD compared with either cancer (35% vs 17%; P =.004) or CVD (35% vs 21%; P =.009) alone. Arrhythmias and encephalopathy were also more frequent in patients with both cancer and CVD compared with those with cancer alone. Conclusions: Patients with a history of both cancer and CVD are at significantly higher risk of experiencing COVID-19–associated adverse outcomes. Aggressive public health measures are needed to mitigate the risks of COVID-19 infection in this vulnerable patient population.
Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma
Authors: Jennifer L Gardell, Lisa R Matsumoto, Harrison Chinn, Kole R DeGolier, Shannon A Kreuser, Brooke Prieskorn, Stephanie Balcaitis, Amira Davis, Richard G Ellenbogen, Courtney A Crane
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Targeted and effective treatment options are needed for solid tumors, including glioblastoma (GBM), where survival rates with standard treatments are typically less than 2 years from diagnosis. Solid tumors pose many barriers to immunotherapies, including therapy half-life and persistence, tumor penetrance, and targeting. Therapeutics delivered systemically may not traffic to the tumor site. If cellular therapies or drugs are able to access the tumor site, or can be delivered directly within the tumor, treatments may not persist for the duration necessary to reduce or eliminate tumor burden. An approach that allows durable and titratable local therapeutic protein delivery could improve antitumor efficacy while minimizing toxicities or unwanted on-target, off-tissue effects. Methods In this study, human monocyte-derived macrophages were genetically engineered to secrete a bispecific T cell engager (BiTE) specific to the mutated epidermal growth factor variant III (EGFRvIII) expressed by some GBM tumors. We investigated the ability of lentivirally modified macrophages to secrete a functional BiTE that can bind target tumor antigen and activate T cells. Secreted BiTE protein was assayed in a range of T cell functional assays in vitro and in subcutaneous and intracranial GBM xenograft models. Finally, we tested genetically engineered macrophages (GEMs) secreting BiTE and the proinflammatory cytokine interleukin (IL)-12 to amplify T cell responses in vitro and in vivo. Results Transduced human macrophages secreted a lentivirally encoded functional EGFRvIII-targeted BiTE protein capable of inducing T cell activation, proliferation, degranulation, and killing of antigen-specific tumor cells. Furthermore, BiTE secreting macrophages reduced early tumor burden in both subcutaneous and intracranial mouse models of GBM, a response which was enhanced using macrophages that were dual transduced to secrete both the BiTE protein and single chain IL-12, preventing tumor growth in an aggressive GBM model. Conclusions The ability of macrophages to infiltrate and persist in solid tumor tissue could overcome many of the obstacles associated with systemic delivery of immunotherapies. We have found that human GEMs can locally and constitutively express one or more therapeutic proteins, which may help recruit T cells and transform the immunosuppressive tumor microenvironment to better support antitumor immunity.
Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, <i>FLT3</i>-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy
Authors: Jorge Sierra, Pau Montesinos, Xavier Thomas, Laimonas Griškevičius, Thomas Cluzeau, Denis Caillot, Ollivier Legrand, Clara Minotti, Mario Luppi, Firas Farkas, Bourras-Rezki Bengoudifa, Geralyn Gilotti, Sejla Hodzic, Alessandro Rambaldi, Adriano Venditti
Journal: Blood (2020)
THU0053 Inhibition of arachidonic acid release from human peripheral mononuclear cells by heat shock treatment and geldanamycin
Authors: S Szanto, P Csermely, I Kovács, J Csongor, GY Szegedi, S Sipka
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Arachidonic acid and its derivatives play an important role in inflammation including arthritis. <h3>Objectives</h3> To investigate the effects of heat shock (HS) treatment and geldanamycin (GM) on the release of arachidonic acid (AA) from human peripheral blood human mononuclear cells (PBMCs) (monocytes and lymphocytes). <h3>Methods</h3> Mononuclear cells prepared from blood of healthy subjects were preincubated with 3H-AA. The release of 3H-AA incorporated into the membrane was studied after pretreatment of cells by HS (43°C, 1 h), GM and prednisolone sodium succinate (PRED). The activation of AA producing enzymes took place by the addition of phorbol 12-myristate 13-acetate (PMA) or by the combination of PMA and calcium ionophore A 23187. <h3>Results</h3> The release of AA by mononuclear cells was dose dependently inhibited by GM similarly to PRED. The treatment of cells by HS also inhibited the release of AA. An additivity was found in the inhibitions induced by GM, PRED and HS. <h3>Conclusion</h3> HS treatment can decrease the release of AA from human mononuclear cells. GM also results in a dose dependent inhibition of AA release. In the mechanism of additivity In the mechanism of additivity found when HS and GM were applied concurrently, the increased blocking of mitogen-activated kinase cascade could be involved. In the additivity induced by HS + PRED and GM + PRED combinations different pathways, the MAPK (HS, GM) and some transcription factors (PRED) simultaneously could play a role. The inhibitory effect of GM on the AA release from mononuclear cells can be a new element in its antiinflammatory actions.
Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma
Authors: Phei Er Saw, Xiaoding Xu, Bo Ram Kang, Jungsul Lee, Yeo Song Lee, Chungyeul Kim, Hyungsin Kim, Shin-Hyuk Kang, Yoo Jin Na, Hong Joo Moon, Joo Han Kim, Youn-Kwan Park, Wonki Yoon, Jong Hyun Kim, Taek-Hyun Kwon, Chulhee Choi, Sangyong Jon, Kyuha Chong
Journal: Theranostics (2020)

Extra-domain B of fibronectin (EDB-FN) is an alternatively spliced form of fibronectin with high expression in the extracellular matrix of neovascularized tissues and malignant cancer cells.In this study, we evaluated the practicality of using EDB-FN as a biomarker and therapeutic target for malignant gliomas (MGs), representative intractable diseases involving brain tumors.Methods: The microarray-and sequence-based patient transcriptomic database 'Oncopression' and tissue microarray of MG patient tissue samples were analyzed.EDB-FN data were extracted and evaluated from 23,344 patient samples of 17 types of cancer to assess its effectiveness and selectivity as a molecular target.To strengthen the results of the patient data analysis, the utility of EDB-FN as a molecular marker and target for MG was verified using active EDB-FN-targeting ultrasmall lipidic micellar nanoparticles (~12 nm), which had a high drug-loading capacity and were efficiently internalized by MG cells in vitro and in vivo.Results: Brain tumors had a 1.42-fold cancer-to-normal ratio (p < 0.0001), the second highest among 17 cancers after head and neck cancer.Patient tissue microarray analysis showed that the EDB-FN high-expression group had a 5.5-fold higher risk of progression than the EDB-FN low-expression group (p < 0.03).By labeling docetaxel-containing ultrasmall micelles with a bipodal aptide targeting EDB-FN (termed APTEDB-DSPE-DTX), we generated micelles that could specifically bind to MG cells, leading to superior antitumor efficacy of EDB-FN-targeting nanoparticles compared to nontargeting controls.Conclusions: Taken together, these results show that EDB-FN can be an effective drug delivery target and biomarker for MG.
Differences in the Mutational Landscape of Myeloid Malignancies (acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasm) and Their Clinical Impact
Authors: María Poza, Rafael Colmenares, Alba González, Noemi Alvarez, Gonzalo Carreño Gomez-Tarragona, Esther Onecha, María Teresa Cedena, Pilar Martínez, Juan Manuel de la Rosa, Inmaculada Rapado, Eva Barragán, Pau Montesinos, Rafael Llobet, Miguel Sanz, Joaquin Martinez-Lopez, Rosa Ayala
Journal: Blood (2020)